spacer
home > pmps > autumn 2003 > who nose how far nasal delivery can go?
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Who Nose How Far Nasal Delivery Can Go?

Nasal delivery has traditionally been restricted to topically acting substances used to treat the common cold and nasal allergies. Recently however, there has been increased interest in the nose as an alternative to oral delivery and injection for many systemic drugs and vaccines. The highly vascularised and immunogenic nasal mucosa offers potential advantages in terms of quick action, improved bio-availability and patient compliance as well as improved immune response for vaccines.

Faced with surging drug development costs and fierce generic competition, pharmaceutical companies are under increasing pressure to find ways to increase and prolong the profitability of both existing and new products. In addition, many of the advanced molecules being developed by biotechnology companies require more efficient delivery than that offered by conventional delivery routes and systems. The challenge of optimising the bio-availability and patient compliance of these expensive molecules are other significant drivers for the development of novel drug delivery systems. If successful, reformulation allied with novel delivery systems provide powerful tools for improving efficiency and differentiating a product from those of competitors.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Per Gisle Djupesland, Head of R&D and Co-Founder of OptiNose AS

Dr Per Gisle Djupesland is Co-Founder, Head of R&D and Chairman of OptiNose AS, a Norwegian R&D company developing a novel concept for nasal delivery of drugs and vaccines. He is a specialist in Otorhinolaryngology with a PhD in Nasal Physiology from the University of Oslo and has been Research Fellow at the University of Toronto, Canada. He has a degree in International Health and Tropical Medicine from Paris, France, and has been Project Manager for a large-scale vaccination trial in the Norwegian Armed Forces.

spacer
Dr Per Gisle Djupesland
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Turkish Cargo includes Sheremetyevo Airport near Moscow to its cargo flights network.

As the fastest growing brand among the global air cargo carriers with its extensive flights network, Turkish Cargo included Sheremetyevo Airport (SVO), known as being the most important airport in Russia in terms of cargo activities, to its direct cargo flight destinations network.
More info >>

White Papers

Protein Therapeutics

Reading Scientific Services Ltd (RSSL)


More info >>

 
Industry Events

FlyPharma Europe

22-23 October 2019, Copenhagen, Denmark

The FlyPharma Conference Europe 2019 is aimed at forward-thinking individuals and businesses that are ready to uncover the potential in their pharma supply chain. The event offers an interactive platform to discuss current and future challenges within pharma and cargo, with topics including market trends, cold chain innovations, latest regulatory demands, security technology, and how to encourage collaboration between supply chain players. There will be plenty of networking opportunities, including a complimentary evening networking event, where delegates can meet and catch up with senior and executive pharma and cargo professionals gaining strong, new industry contacts and building on existing ones.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement